Dr. Mohammad T. Sheikh
General Practice (General Practice Physician)
- Medicare participating
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 18
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
General Practice Physician primary
FL license ME86678
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 18
- Services billed
- 80
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 55 | 22 |
| Insertion of needle into vein for collection of blood sample | 20 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 6 payments worth $253 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $253 |
|---|
| Food and Beverage | $242 |
|---|---|
| Education | $10.55 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP May 13, 2025 | Education BREZTRI · Respiratory · in-kind Company’s descriptionJournal Article | $5.55 |
| AstraZeneca Pharmaceuticals LP May 13, 2025 | Education BREZTRI · Respiratory · in-kind Company’s descriptionLiterature | $5.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 2 companies. The companies reported $842,118 in research payments for these studies, mostly to the institutions running them.
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Sanofi US Services Inc. · Active, not recruiting · NCT06676319 - A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
AstraZeneca Pharmaceuticals LP - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulm…
AstraZeneca Pharmaceuticals LP - Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmon…
AstraZeneca Pharmaceuticals LP - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
Sanofi US Services Inc. · Terminated · NCT06033833 - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chron…
AstraZeneca Pharmaceuticals LP - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
Sanofi US Services Inc. · Enrolling by invitation · NCT06609239 - A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Sanofi US Services Inc. · Completed · NCT06208306 - Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
Sanofi US Services Inc. · Completed · NCT05421598
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.